221 related articles for article (PubMed ID: 15994963)
1. Human malignant melanomas express receptors for luteinizing hormone releasing hormone allowing targeted therapy with cytotoxic luteinizing hormone releasing hormone analogue.
Keller G; Schally AV; Gaiser T; Nagy A; Baker B; Westphal G; Halmos G; Engel JB
Cancer Res; 2005 Jul; 65(13):5857-63. PubMed ID: 15994963
[TBL] [Abstract][Full Text] [Related]
2. Receptors for luteinizing hormone releasing hormone expressed on human renal cell carcinomas can be used for targeted chemotherapy with cytotoxic luteinizing hormone releasing hormone analogues.
Keller G; Schally AV; Gaiser T; Nagy A; Baker B; Halmos G; Engel JB
Clin Cancer Res; 2005 Aug; 11(15):5549-57. PubMed ID: 16061872
[TBL] [Abstract][Full Text] [Related]
3. Receptors for luteinizing hormone releasing hormone (LHRH) expressed in human non-Hodgkin's lymphomas can be targeted for therapy with the cytotoxic LHRH analogue AN-207.
Keller G; Schally AV; Gaiser T; Nagy A; Baker B; Halmos G; Engel JB
Eur J Cancer; 2005 Sep; 41(14):2196-202. PubMed ID: 16182122
[TBL] [Abstract][Full Text] [Related]
4. Effective treatment of experimental human endometrial cancers with targeted cytotoxic luteinizing hormone-releasing hormone analogues AN-152 and AN-207.
Engel JB; Keller G; Schally AV; Nagy A; Chism DD; Halmos G
Fertil Steril; 2005 Apr; 83 Suppl 1():1125-33. PubMed ID: 15831285
[TBL] [Abstract][Full Text] [Related]
5. Targeted doxorubicin-containing luteinizing hormone-releasing hormone analogue AN-152 inhibits the growth of doxorubicin-resistant MX-1 human breast cancers.
Bajo AM; Schally AV; Halmos G; Nagy A
Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3742-8. PubMed ID: 14506166
[TBL] [Abstract][Full Text] [Related]
6. Preclinical evaluation of targeted cytotoxic luteinizing hormone-releasing hormone analogue AN-152 in androgen-sensitive and insensitive prostate cancers.
Letsch M; Schally AV; Szepeshazi K; Halmos G; Nagy A
Clin Cancer Res; 2003 Oct; 9(12):4505-13. PubMed ID: 14555524
[TBL] [Abstract][Full Text] [Related]
7. Effective treatment of metastatic MDA-MB-435 human estrogen-independent breast carcinomas with a targeted cytotoxic analogue of luteinizing hormone-releasing hormone AN-207.
Chatzistamou L; Schally AV; Nagy A; Armatis P; Szepeshazi K; Halmos G
Clin Cancer Res; 2000 Oct; 6(10):4158-65. PubMed ID: 11051271
[TBL] [Abstract][Full Text] [Related]
8. [Receptors for luteinizing hormone releasing hormone expressed on melanoma, renal cell carcinoma and non Hodgkin lymphoma can be used for targeted chemotherapy with cytotoxic luteinizing hormone releasing hormone analogues].
Gaiser T; Rüschoff J; Schally AV; Keller G; Engel JB
Verh Dtsch Ges Pathol; 2006; 90():186-92. PubMed ID: 17867596
[TBL] [Abstract][Full Text] [Related]
9. Complete regression of MX-1 human breast carcinoma xenografts after targeted chemotherapy with a cytotoxic analog of luteinizing hormone-releasing hormone, AN-207.
Kahán Z; Nagy A; Schally AV; Halmos G; Arencibia JM; Groot K
Cancer; 1999 Jun; 85(12):2608-15. PubMed ID: 10375109
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of human experimental prostate cancers by a targeted cytotoxic luteinizing hormone-releasing hormone analog AN-207.
Stangelberger A; Schally AV; Nagy A; Szepeshazi K; Kanashiro CA; Halmos G
Prostate; 2006 Feb; 66(2):200-10. PubMed ID: 16173040
[TBL] [Abstract][Full Text] [Related]
11. Therapy of experimental hepatic cancers with cytotoxic peptide analogs targeted to receptors for luteinizing hormone-releasing hormone, somatostatin or bombesin.
Szepeshazi K; Schally AV; Treszl A; Seitz S; Halmos G
Anticancer Drugs; 2008 Apr; 19(4):349-58. PubMed ID: 18454045
[TBL] [Abstract][Full Text] [Related]
12. Targeted chemotherapy for triple-negative breast cancers via LHRH receptor.
Föst C; Duwe F; Hellriegel M; Schweyer S; Emons G; Gründker C
Oncol Rep; 2011 May; 25(5):1481-7. PubMed ID: 21331448
[TBL] [Abstract][Full Text] [Related]
13. Effective targeted chemotherapy using AEZS-108 (AN-152) for LHRH receptor-positive pancreatic cancers.
Gründker C; Ernst J; Reutter MD; Ghadimi BM; Emons G
Oncol Rep; 2011 Sep; 26(3):629-35. PubMed ID: 21667032
[TBL] [Abstract][Full Text] [Related]
14. Luteinizing hormone-releasing hormone receptor-targeted chemotherapy using AN-152.
Emons G; Sindermann H; Engel J; Schally AV; Gründker C
Neuroendocrinology; 2009; 90(1):15-8. PubMed ID: 19521066
[TBL] [Abstract][Full Text] [Related]
15. Effective therapy of experimental human malignant melanomas with a targeted cytotoxic somatostatin analogue without induction of multi-drug resistance proteins.
Keller G; Schally AV; Nagy A; Baker B; Halmos G; Engel JB
Int J Oncol; 2006 Jun; 28(6):1507-13. PubMed ID: 16685451
[TBL] [Abstract][Full Text] [Related]
16. Internalization of cytotoxic analog AN-152 of luteinizing hormone-releasing hormone induces apoptosis in human endometrial and ovarian cancer cell lines independent of multidrug resistance-1 (MDR-1) system.
Günthert AR; Gründker C; Bongertz T; Schlott T; Nagy A; Schally AV; Emons G
Am J Obstet Gynecol; 2004 Oct; 191(4):1164-72. PubMed ID: 15507937
[TBL] [Abstract][Full Text] [Related]
17. LH-RH receptors in human colorectal cancers: unexpected molecular targets for experimental therapy.
Szepeshazi K; Schally AV; Halmos G
Int J Oncol; 2007 Jun; 30(6):1485-92. PubMed ID: 17487370
[TBL] [Abstract][Full Text] [Related]
18. AEZS-108 : a targeted cytotoxic analog of LHRH for the treatment of cancers positive for LHRH receptors.
Engel J; Emons G; Pinski J; Schally AV
Expert Opin Investig Drugs; 2012 Jun; 21(6):891-9. PubMed ID: 22577891
[TBL] [Abstract][Full Text] [Related]
19. Induction of apoptosis by AN-152, a cytotoxic analog of luteinizing hormone-releasing hormone (LHRH), in LHRH-R positive human breast cancer cells is independent of multidrug resistance-1 (MDR-1) system.
Günthert AR; Gründker C; Bongertz T; Nagy A; Schally AV; Emons G
Breast Cancer Res Treat; 2004 Oct; 87(3):255-64. PubMed ID: 15528968
[TBL] [Abstract][Full Text] [Related]
20. Effective inhibition of experimental human ovarian cancers with a targeted cytotoxic bombesin analogue AN-215.
Engel JB; Keller G; Schally AV; Halmos G; Hammann B; Nagy A
Clin Cancer Res; 2005 Mar; 11(6):2408-15. PubMed ID: 15788692
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
